Literature DB >> 16061895

Can we better prioritize resources for cost-utility research?

Peter J Neumann1, Allison B Rosen, Dan Greenberg, Natalia V Olchanski, Richa Pande, Richard H Chapman, Patricia W Stone, Silvia Ondategui-Parra, John Nadai, Joanna E Siegel, Milton C Weinstein.   

Abstract

PURPOSE: We examined 512 published cost-utility analyses (CUAs) in the U.S. and other developed countries from 1976 through 2001 to determine: 1) the types of interventions studied; 2) whether they cover diseases and conditions with the highest burden; and, 3) to what extent they have covered leading health concerns defined by the Healthy People 2010 report. DATA AND METHODS: We compared rankings of the most common diseases covered by the CUAs to rankings of U.S. disease burden. We also examined the extent to which CUAs covered key Healthy People 2010 priorities.
RESULTS: CUAs have focused mostly on pharmaceuticals (40%) and surgical procedures (16%). When compared to leading causes of DALYs, the data show overrepresentation of CUAs in cerebrovascular disease, diabetes, breast cancer, and HIV/AIDS, and underrepresentation in depression and bipolar disorder, injuries, and substance abuse disorders. Few CUAs have targeted Healthy People 2010 areas, such as physical activity.
CONCLUSIONS: Published CUAs are associated with burden measures, but have not covered certain important health problems. These discrepancies do not alone indicate that society has been targeting resources for research inefficiently, but they do suggest the need to formalize the question of where each CUA research dollar might do the most good.

Entities:  

Mesh:

Year:  2005        PMID: 16061895     DOI: 10.1177/0272989X05276853

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  16 in total

1.  A systematic review of economic evaluation literature in Thailand: are the data good enough to be used by policy-makers?

Authors:  Yot Teerawattananon; Steve Russell; Miranda Mugford
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Measuring the value of public health systems: the disconnect between health economists and public health practitioners.

Authors:  Peter J Neumann; Peter D Jacobson; Jennifer A Palmer
Journal:  Am J Public Health       Date:  2008-10-15       Impact factor: 9.308

3.  Lack of Cost-Effectiveness Analyses to Address Healthy People 2020 Priority Areas.

Authors:  Peter J Neumann; Megan Farquhar; Colby L Wilkinson; Mackenzie Lowry; Marthe Gold
Journal:  Am J Public Health       Date:  2016-09-15       Impact factor: 9.308

4.  30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement.

Authors:  Peter J Neumann; Chi-Hui Fang; Joshua T Cohen
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

5.  Longitudinal association of preference-weighted health-related quality of life measures and substance use disorder outcomes.

Authors:  Jeffrey M Pyne; Shanti Tripathi; Michael French; Kathryn McCollister; Richard C Rapp; Brenda M Booth
Journal:  Addiction       Date:  2011-03       Impact factor: 6.526

6.  Characteristics and quality of pediatric cost-utility analyses.

Authors:  Seija K Kromm; Jennifer Bethell; Ferne Kraglund; Sarah A Edwards; Audrey Laporte; Peter C Coyte; Wendy J Ungar
Journal:  Qual Life Res       Date:  2011-10-29       Impact factor: 4.147

7.  Burden of disease and economic evaluation of healthcare interventions: are we investigating what really matters?

Authors:  Ferrán Catalá-López; Anna García-Altés; Elena Alvarez-Martín; Ricard Gènova-Maleras; Consuelo Morant-Ginestar; Antoni Parada
Journal:  BMC Health Serv Res       Date:  2011-04-13       Impact factor: 2.655

Review 8.  HEE-GER: a systematic review of German economic evaluations of health care published 1990-2004.

Authors:  David L B Schwappach; Till A Boluarte
Journal:  BMC Health Serv Res       Date:  2007-01-12       Impact factor: 2.655

9.  The economic value of personalized medicine tests: what we know and what we need to know.

Authors:  Kathryn A Phillips; Julie Ann Sakowski; Julia Trosman; Michael P Douglas; Su-Ying Liang; Peter Neumann
Journal:  Genet Med       Date:  2013-10-17       Impact factor: 8.822

10.  Review of Australian health economic evaluation - 245 interventions: what can we say about cost effectiveness?

Authors:  Kim Dalziel; Leonie Segal; Duncan Mortimer
Journal:  Cost Eff Resour Alloc       Date:  2008-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.